Prestige Consumer Healthcare Inc
NYSE:PBH
Prestige Consumer Healthcare Inc
Accounts Receivables
Prestige Consumer Healthcare Inc
Accounts Receivables Peer Comparison
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Prestige Consumer Healthcare Inc
NYSE:PBH
|
Accounts Receivables
$174.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
4%
|
CAGR 10-Years
10%
|
|
Johnson & Johnson
NYSE:JNJ
|
Accounts Receivables
$14.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accounts Receivables
$9.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
18%
|
|
Pfizer Inc
NYSE:PFE
|
Accounts Receivables
$11.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
2%
|
|
Merck & Co Inc
NYSE:MRK
|
Accounts Receivables
$11.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
Eli Lilly and Co
NYSE:LLY
|
Accounts Receivables
$7.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
See Also
What is Prestige Consumer Healthcare Inc's Accounts Receivables?
Accounts Receivables
174.3m
USD
Based on the financial report for Dec 31, 2023, Prestige Consumer Healthcare Inc's Accounts Receivables amounts to 174.3m USD.
What is Prestige Consumer Healthcare Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
10%
Over the last year, the Accounts Receivables growth was 11%. The average annual Accounts Receivables growth rates for Prestige Consumer Healthcare Inc have been 15% over the past three years , 4% over the past five years , and 10% over the past ten years .